Parameter
| Biomarker | microRNA (miR-21, miR-155) | Full name | MicroRNA-21 / MicroRNA-155 | Molecular Type | Nucleic acid（miRNA） |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Monitoring, prognosis |
| Disease | Breast Cancer | Disease Subtypes | / | ||
| Organ | Breast | Test Sample / Technology Platform | Serum / Plasma / Tumor Tissue (Real-time Fluorescence Quantitative PCR qPCR, NGS) | ||
| Pathobiological Mechanisms | miR-21 promotes cell proliferation by inhibiting tumor suppressor genes (such as PTEN); miR-155 regulates inflammatory pathways and the immune microenvironment, facilitating tumor progression. | ||||
| Clinical Availability Status | Research verification: Liquid biopsy (serum miRNA) shows potential in early diagnosis and prognosis stratification, but has not yet been widely used clinically. | ||||
| Notes and Dynamics | miR-21 and miR-155 can serve as combined markers to enhance diagnostic accuracy; drugs targeting miRNAs are currently in preclinical research. | ||||